We further provide evidence that Rb1 and compound K can chemosensitize CSCs to clinical anticancer drugs cisplatin and paclitaxel, inducing a synergistic cytotoxicity via Wnt/β-catenin signaling and epithelial-to-mesenchymal transition (EMT) regulation, both attractive targets for cancer treatment. This evidence concerns the gene RB1 and cancer.